Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-15 19:12 | 2025-08-13 | NATR | NATURES SUNSHINE PRODUCTS INC | Brower Nathan G | Officer | SELL | $16.54 | 9,996 | $165,334 | 48,277 |
| 2025-08-15 23:31 | 2025-08-14 | AMRX | Amneal Pharmaceuticals Inc. | Shah Nikita | Officer | SELL | $9.29 | 71,694 | $666,037 | 267,235 |
| 2025-08-15 23:30 | 2025-08-15 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | Officer | SELL | $7.36 | 15,000 | $110,358 | 462,666 |
| 2025-08-15 23:30 | 2025-08-14 | ABEO | Abeona Therapeutics Inc. | Crombez Eric | Director | SELL | $6.93 | 4,718 | $32,683 | 42,427 |
| 2025-08-15 23:40 | 2025-08-13 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | OPT+S | $304.56 | 89,794 | $27,347,634 | 0 |
| 2025-08-15 23:38 | 2025-08-13 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $300.45 | 11,013 | $3,308,877 | 0 |
| 2025-08-15 23:31 | 2025-08-13 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $15.00 | 13,712 | $205,680 | 19,631 |
| 2025-08-16 00:50 | 2025-08-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | Officer | OPT+S | $46.56 | 10,000 | $465,632 | 97,130 |
| 2025-08-15 23:07 | 2025-08-13 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | OPT+S | $46.66 | 1,542 | $71,950 | 38,867 |
| 2025-08-16 02:23 | 2025-08-13 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $61.11 | 32,174 | $1,966,285 | 592,908 |
| 2025-08-16 02:11 | 2025-08-14 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $2.00 | 4,900 | $9,800 | 1,974,172 |
| 2025-08-15 23:57 | 2025-08-13 | XERS | Xeris Biopharma Holdings, Inc. | JOHNSON JOHN | Director | SELL | $7.32 | 107,500 | $786,459 | 833,483 |
| 2025-08-15 23:09 | 2025-08-06 | RNA | Avidity Biosciences, Inc. | MacLean Michael F | Officer | SELL | $42.73 | 30,914 | $1,320,844 | 65,806 |
| 2025-08-15 23:09 | 2025-08-13 | ALDX | Aldeyra Therapeutics Inc. | Alfieri Michael | Officer | BUY | $5.30 | 2,500 | $13,250 | 2,500 |
| 2025-08-15 23:30 | 2025-08-13 | AMRX | Amneal Pharmaceuticals Inc. | Konidaris Tasos | Officer | SELL | $9.33 | 499,730 | $4,663,081 | 122,152 |
| 2025-08-16 00:08 | 2025-08-13 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dreyer Scott | Officer | OPT+S | $38.03 | 4,861 | $184,881 | 103,613 |
| 2025-08-15 23:12 | 2025-08-13 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Rubric Capital Management LP | 10% owner | SELL | $37.85 | 25,000 | $946,250 | 3,132,743 |
| 2025-08-15 23:05 | 2025-08-14 | ALNY | Alnylam Pharmaceuticals Inc. | Ausiello Dennis A | Director | OPT+S | $436.58 | 31,448 | $13,729,536 | 911 |
| 2025-08-16 01:04 | 2025-08-15 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | BATE KENNETH | Director | OPT+S | $365.20 | 10,000 | $3,652,009 | 2,627 |
| 2025-08-15 23:23 | 2025-08-15 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $38.42 | 5,000 | $192,100 | 383,108 |
| 2025-08-14 23:15 | 2025-08-13 | DSGN | Design Therapeutics, Inc. | William Arsani | Director | SELL | $5.25 | 562,627 | $2,953,792 | 1,000,000 |
| 2025-08-15 02:43 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Officer | OPT+S | $13.39 | 2,491 | $33,360 | 23,645 |
| 2025-08-15 02:42 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Director, Officer | OPT+S | $13.39 | 1,907 | $25,539 | 23,400 |
| 2025-08-15 00:22 | 2025-08-12 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $34.84 | 96,387 | $3,357,844 | 536,962 |
| 2025-08-15 01:02 | 2025-08-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $12.93 | 11,365 | $146,987 | 92,891 |
| 2025-08-14 23:20 | 2025-08-12 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Mazzariello Gina | Officer | SELL | $8.21 | 30,000 | $246,150 | 156,969 |
| 2025-08-15 02:43 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Carruthers R Michael | Officer | OPT+S | $13.39 | 1,428 | $19,124 | 86,162 |
| 2025-08-15 02:41 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer | OPT+S | $13.39 | 2,862 | $38,329 | 25,361 |
| 2025-08-15 01:48 | 2025-08-12 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Smith Hunter C | Officer | OPT+S | $96.29 | 28,088 | $2,704,624 | 116,915 |
| 2025-08-15 00:00 | 2025-08-12 | ABBV | AbbVie Inc. | SALEKI-GERHARDT AZITA | Officer | OPT+S | $198.42 | 42,370 | $8,407,055 | 177,292 |
| 2025-08-14 23:05 | 2025-08-12 | KURA | Kura Oncology, Inc. | WILSON TROY EDWARD | Director, Officer | BUY | $6.06 | 50,000 | $303,200 | 50,968 |
| 2025-08-14 23:59 | 2025-08-12 | KNSA | Kiniksa Pharmaceuticals International, plc | Malley Thomas | Director | OPT+S | $32.96 | 177,769 | $5,859,817 | 12,546 |
| 2025-08-15 04:35 | 2025-08-14 | BHC | Bausch Health Companies Inc. | Paulson John | Director | BUY | $9.00 | 34,721,118 | $312,490,062 | 70,755,869 |
| 2025-08-14 23:12 | 2025-08-13 | LLY | ELI LILLY & Co | Alvarez Ralph | Director | BUY | $660.25 | 758 | $500,473 | 758 |
| 2025-08-14 23:27 | 2025-08-12 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.25 | 5,500 | $28,875 | 0 |
| 2025-08-15 01:47 | 2025-08-12 | RYTM | RHYTHM PHARMACEUTICALS, INC. | German Christopher Paul | Officer | OPT+S | $95.00 | 1,500 | $142,500 | 922 |
| 2025-08-15 02:43 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | Officer | OPT+S | $13.39 | 2,098 | $28,097 | 10,214 |
| 2025-08-15 02:42 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | KOCH KEVIN | Director, Officer | OPT+S | $13.39 | 7,972 | $106,764 | 30,615 |
| 2025-08-14 23:21 | 2025-08-12 | INSM | INSMED Inc | SHAROKY MELVIN MD | Director | SELL | $121.58 | 10,000 | $1,215,800 | 290,616 |
| 2025-08-15 00:43 | 2025-08-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $88.87 | 400 | $35,548 | 76,474 |
| 2025-08-15 00:46 | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc. | Gutwerg Ori | Officer | SELL | $86.53 | 5,873 | $508,191 | 84,024 |
| 2025-08-15 00:48 | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc. | Lalwani Nikhil | Director, Officer | SELL | $85.93 | 56,960 | $4,894,573 | 411,219 |
| 2025-08-15 00:40 | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc. | CAREY STEPHEN P. | Officer | OPT+S | $86.07 | 50,000 | $4,303,500 | 180,863 |
| 2025-08-15 00:53 | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc. | Rowland Thomas Andrew | Officer | SELL | $85.71 | 4,975 | $426,407 | 40,794 |
| 2025-08-15 00:38 | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc. | HAUGHEY THOMAS | Director | SELL | $85.93 | 19,341 | $1,661,972 | 36,521 |
| 2025-08-14 04:09 | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | Officer | SELL | $10.43 | 185 | $1,930 | 8,849 |
| 2025-08-14 04:08 | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Officer | SELL | $10.43 | 267 | $2,785 | 8,957 |
| 2025-08-14 04:06 | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | Officer | SELL | $10.43 | 267 | $2,785 | 8,759 |
| 2025-08-14 01:37 | 2025-08-12 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | OPT+S | $47.79 | 12,500 | $597,326 | 197,484 |
| 2025-08-14 01:37 | 2025-08-11 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | SELL | $48.59 | 30,000 | $1,457,595 | 490,757 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.